Targeting glycoproteins or glycolipids and their metabolic pathways for antiparasite therapy.
Carbohydrate-based therapy, known as glycotherapeutics, is a new and emerging field that promises to be the future hope for combating kinetoplastid infections more efficiently and effectively. Targeting novel glycoproteins/lipids, which are important disease determinants of kinetoplastid diseases, have helped in the development of this field. Better and refined understanding of all the available data would possibly help us in providing a future direction for rational drug design and better disease management. This review intends to focus on such lines, which will give us an insight into the future hope for development of novel therapeutic strategies through glycobiological platform for combating kinetoplastid infections.
Bandyopadhyay
Sumi Mukhopadhyay nee
SM
Immunobiology Division, Indian Institute of Chemical Biology, 4 Raja S.C. Mullick Road, Jadavpur, Kolkata 700 032, India.
Mandal
Chitra
C
D000818:Animals; D006001:Glycoconjugates / Q000378:metabolism / Q000502:physiology; D006017:Glycolipids / Q000378:metabolism* / Q000502:physiology; D006023:Glycoproteins / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D011528:Protozoan Infections / Q000188:drug therapy* / Q000378:metabolism / Q000469:parasitology; D015800:Protozoan Proteins / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D014344:Trypanocidal Agents / Q000494:pharmacology*; D014351:Trypanosomatina / Q000187:drug effects* / Q000378:metabolism
D006001:Glycoconjugates; D006017:Glycolipids; D006023:Glycoproteins; D015800:Protozoan Proteins; D014344:Trypanocidal Agents